A tiny engineered particle cooked up at Oregon State University is pulling off a big trick in mice: when injected and hit with near-infrared light, it heats up and wipes out melanoma tumors while leaving most nearby healthy tissue alone. In lab tests, a single low-power laser session, kept below established safety thresholds for skin, completely ablated aggressive tumors in the animal model. The work, led by Olena Taratula and postdoctoral researcher Prem Singh at OSU's College of Pharmacy, is being pitched as a potential less-invasive alternative to wide surgical excisions, although researchers say it will need much more testing before anyone tries it in people.
How the particles make heat
The platform is built around gold nanorods wrapped in an iron-cobalt shell and packed tightly with a near-infrared dye. By exploiting resonance energy transfer, the team boosts the conversion of light to heat so the particles can reach tumor-killing temperatures under relatively weak NIR illumination. As detailed in Advanced Functional Materials, this design generates substantially more heat than comparable agents at similar wavelengths, which is what lets the researchers stay under the skin’s usual safety limit for laser exposure. The same nanostructure also lights up with fluorescence, hinting at the possibility of image-guided ablation in clinical use.
Mouse tests and the power threshold
In the mouse studies, the nanoparticles were administered systemically, then a near-infrared laser was trained on the tumors to trigger localized heating. According to Oregon State University, a single treatment at 0.25 watts per square centimeter, which is below the commonly cited 0.33 W/cm² safety threshold for skin, “completely ablated the tumor,” Taratula said. The team reported only minimal damage to surrounding healthy tissue after treatment.
Why this matters
Melanoma makes up a relatively small slice of skin cancer cases but causes a disproportionate share of deaths. The American Cancer Society projects roughly 112,000 invasive melanoma cases and about 8,510 deaths in the United States in 2026. That is the backdrop for the push toward photothermal therapy, which uses heat to destroy tumors.
As summarized in a technical review of photothermal approaches in Theranostics, many existing PTT systems depend on high-power lasers or on direct injection into the tumor to get hot enough, both of which limit how and where they can be used. The OSU platform was designed to sidestep those constraints by working with lower power and systemic delivery. If these agents can be safely given through the bloodstream and tracked in real time in human patients, clinicians could gain a less-invasive option for local tumor control. That is still a big “if,” and lab success in mice does not automatically translate to safe, effective treatment in people.
Road to clinical use
The researchers say safety and regulatory testing are next on the docket. As reported by KGW, the lab estimates that clinical trials could be anywhere from a year away to as much as a decade off, depending on funding, additional preclinical results and how quickly regulators weigh in. Planned follow-up animal studies will look at how the nanoparticles distribute through the body, what they do to the immune system and whether there are any long-term safety red flags before the team seeks approval for human testing.
Takeaway for patients and clinicians
The project was conducted at Oregon State’s College of Pharmacy with backing from the National Cancer Institute and internal OSU programs, according to Oregon State University. For patients and oncologists, the idea of a low-power, image-guided photothermal agent is undeniably appealing. At the same time, cancer specialists are quick to note that a long list of therapies that look curative in mice never make it to standard care in humans.
The OSU team says it will release additional preclinical data as it comes in and is looking for partners to help move the platform toward human trials. For now, the laser-powered nanoparticles remain a promising, very early stage concept rather than a ready-for-prime-time melanoma cure.
